Clinical trials: Skin Manifestations
Immune Thrombocytopenic Purpura (ITP)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed.
- Trial name
- NCT06722235
- Testing
- Mezagitamab
- Where
- 124 sites in United States, Australia and 16 more
- Volunteers
- 171 people
- Sponsor
- Takeda
Immune Thrombocytopenic Purpura (ITP)
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed.
- Trial name
- NCT06948318
- Testing
- Mezagitamab
- Where
- 118 sites in United States, Australia and 13 more
- Volunteers
- 150 people
- Sponsor
- Takeda
Skin Manifestations, COVID
Assessment of Chilbains Occuring During Covid-19 Infection
Some patients infected by covid-19 develop skin manifestations. These manifestations are still not well known and there pathophysiology remain unclear.
- Conditions
- Skin Manifestations, COVID, Chilblains
- Trial name
- ChilblainCOVID (NCT04344119)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Metabolic Disease, Neurological and Mental Health Conditions
Singapore PREconception Study of Long-Term Maternal and Child Outcomes
We aim to test the following primary hypothesis that nutrition, lifestyle, and maternal emotional health prior to pregnancy and/or during the first trimester alter the expression of metabolic or neurodevelopmental endophenotypes…
- Conditions
- Metabolic Disease, Neurological and Mental Health Conditions, Genetics Predisposition, Skin Condition
- Trial name
- S-PRESTO (NCT03531658)
- Where
- Singapore
- Volunteers
- 1,054 people, healthy volunteers welcome
- Sponsor
- KK Women's and Children's Hospital
Metabolic Diseases, Neurological and Mental Health Conditions
Growing Up in Singapore Towards Healthy Outcomes
This study aims to examine the role of genetic and epigenetic factors, maternal nutrition, lifestyle, emotional health, and other environmental factors in pregnancy or postpartum period that can influence future maternal risk of…
- Conditions
- Metabolic Diseases, Neurological and Mental Health Conditions, Genetic Predisposition, Skin Condition
- Trial name
- GUSTO (NCT01174875)
- Where
- Singapore
- Volunteers
- 1,247 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Skin Manifestations
New Regenerative Approach for Dermal Renovation (Karisma)
Purpose/Objectives of the Study: Regenerative medicine, as well as aesthetic plastic surgery and dermatology field persistently seeks innovative, minimally invasive interventions to enhance skin quality and mitigate signs of…
- Trial name
- Karisma (NCT06152718)
- Testing
- Karisma
- Where
- 2 sites in Italy, Serbia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Palermo
Immune Thrombocytopenia, Blood Platelet Disorder
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.
- Conditions
- Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic
- Trial name
- NCT06291415
- Testing
- HMPL-523
- Where
- 28 sites in United States, Australia and 3 more
- Sponsor
- Hutchmed
Skin Manifestations
Study to Evaluate the Safety and Effectiveness of GP0116
This is a prospective, randomized, evaluator-blinded, comparator-controlled, parallel group, multicenter study in the U.S. for correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs).
- Trial name
- NLF (NCT05987163)
- Testing
- GP0116, Active Comparator: FDA approved dermal filler device (RHA 3)
- Where
- 19 sites in United States, Puerto Rico
- Volunteers
- 186 people
- Sponsor
- Galderma R&D
Dermatologic Diseases, Systemic Diseases With Cutaneous Manifestations
Evaluation and Treatment of Patients With Dermatologic Diseases
This is a training, natural history of disease, and screening protocol for the evaluation, treatment and follow-up of patients with dermatologic diseases and systemic diseases with cutaneous manifestations.
- Trial name
- NCT00001506
- Where
- United States
- Volunteers
- 453 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Skin Aging, Skin Condition
A Clinical Study on Pre-operative Intervention With Products During Aesthetic Medicine
This clinical trial aims to evaluate whether a 14-day pre-operative application of the test product (containing MLYAAT-1002®, a proprietary anti-aging complex) can mitigate skin discomfort during Fotona 4D laser therapy (Frac3…
- Conditions
- Skin Aging, Skin Condition, Skin Manifestations
- Trial name
- NCT06891924
- Testing
- 14-day daily pre-operative application of the formulations containing MLYAAT-1002® before Fotona4D treatment, 14-day daily pre-operative application of the formulations without MLYAAT-1002® before Fotona4D treatment
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Botanee Group Co., Ltd.
Prader-Willi Syndrome, Aggression
Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
This is a placebo-controlled clinical trial to assess whether Guanfacine Extended Release (GXR) reduces aggression and self injurious behavior in individuals with Prader Willi Syndrome (PWS).
- Conditions
- Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes
- Trial name
- PWS-GXR (NCT05657860)
- Testing
- Guanfacine Extended Release
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Maimonides Medical Center
Wrinkle, Skin Laxity
A 28-day Clinical Study on Facial Skin Rejuvenation
This clinical trial aims to learn about the efficacy of MLYAAT-1002® (a proprietary anti-aging complex, MLYAAT is short for "multi-layer anti-ageing technology" ) in female subjects who have newly received the rejuvenation…
- Conditions
- Wrinkle, Skin Laxity, Skin Manifestations, Skin
- Trial name
- NCT06140628
- Testing
- Fotona4D Pro® treatment followed by daily use of formulations containing MLYAAT-1002®, Fotona4D Pro® treatment followed by daily use of formulations without MLYAAT-1002®
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Botanee Group Co., Ltd.
Skin Manifestations, Wrinkle
A 56-day Clinical Study on Facial Skin Rejuvenation
This clinical trial aims to learn about the efficacy of MLYAAT-1002® (a proprietary anti-aging complex, MLYAAT is short for "multi-layer anti-ageing technology" ) in female subjects who have newly received the rejuvenation…
- Conditions
- Skin Manifestations, Wrinkle, Photoaging
- Trial name
- NCT06188338
- Testing
- Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®., Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002®
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Botanee Group Co., Ltd.
Chronic Kidney Diseases, Manifestation, Skin
Mucocutaneous Manifestations in Patients With Chronic Kidney Disease inNewVally and Assuit;Hospital Based Study
1. To study the patterns of mucocutaneous disorders in Chronic Kidney Disease patients in Eldakhla General Hospital, New Valley and in Assiut University hospital . 2.
- Trial name
- NCT05819320
- Testing
- observe pattern of mucocutaneous manifestations in chronic kidney disease patients
- Volunteers
- 140 people
- Sponsor
- Assiut University
Malformations With Skin Manifestations Suggesting Mosaicism
Screening for Chromosomal Microarrangements by CGH-array in Developmental Anomalies of the Skin Suggestive of Mosaicism.
The principal result expected is the discovery of inframicroscopic chromosomal rearrangements in regions of the genome not yet known to be involved, or mutations in known candidate genes; The identification of such a mosaic…
- Trial name
- MOSAÏQUE (NCT01950975)
- Testing
- Peripheral blood samples in EDTA tubes, Skin biopsies
- Where
- France
- Volunteers
- 315 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Skin Manifestations, Antioxidative Stress
Omegia Softgel Clinical Research Program
Evaluate the improvement of regulation of skin and blood index composition after consumption of Omegia® Softgel
- Conditions
- Skin Manifestations, Antioxidative Stress, Eye Strain, Vaginal Disease
- Trial name
- NCT05872178
- Testing
- Omegia® Softgel -B, Omegia® Softgel -A
- Where
- Taiwan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chia Nan University of Pharmacy ＆ Science
Healthy, Skin Manifestations
Facial Skin Clinical and Microbial Profiling From Oral Probiotic Supplementation
The goal of this double-blind randomized clinical trial is to investigate the effects on the skin from oral intake of probiotic supplements in healthy adult men and women.
- Trial name
- NCT05597254
- Testing
- Probiotic with niacin and berry extract, Probiotic without niacin and berry extract
- Where
- Sweden
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Oriflame Cosmetics AB
Skin Manifestations
Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin
The purpose of this study is to compare the tolerability of Differin® (adapalene) Cream, 0.1% to Differin® Lotion, 0.1% in subjects with healthy skin treated once a day for three (3) weeks.
- Trial name
- NCT01046565
- Testing
- adapalene cream 0.1%, adapalene lotion 0.1%
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Skin Manifestations
Tolerability Comparison of Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin
The purpose of this study is to compare the tolerability of Differin® (adapalene) Cream, 0.1% to Differin® Lotion, 0.1% in subjects with healthy skin treated once a day for three (3) weeks.
- Trial name
- NCT01046396
- Testing
- adapalene cream 0.1% and adapalene lotion 0.1%, adapalene lotion 0.1%
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Skin Manifestations
Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin
The purpose of this study is to compare the tolerability of MetroGel® (metronidazole gel) 1% to Finacea® (azelaic acid) Gel 15% in subjects with healthy skin applied according to product labeling for three weeks.
- Trial name
- NCT01139008
- Testing
- metronidazole 1% gel, azelaic acid 15% gel
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Galderma R&D